Chapter 9. Current Challenges in the Adjuvant Therapy of Colon Cancer
- John H. Scholefield1,
- Axel Grothey2,
- Herand Abcarian3 and
- Tim Maughan4
Published Online: 14 JAN 2008
Copyright © 2006 by Blackwell Publishing Ltd
Challenges in Colorectal Cancer
How to Cite
Kim, G. P. and Grothey, A. (2006) Current Challenges in the Adjuvant Therapy of Colon Cancer, in Challenges in Colorectal Cancer (eds J. H. Scholefield, A. Grothey, H. Abcarian and T. Maughan), Blackwell Publishing Ltd, Malden, Massachusetts, USA. doi: 10.1002/9780470753231.ch9
Professor of Surgery, University Hospital, Nottingham, UK
Professor, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA
Turi Josefsen Professor and Chairman, Department of Surgery, University of Illinois College of Medicine, Chicago, Illinois, USA
Professor of Cancer Studies, University of Cardiff, Cardiff, UK
- Published Online: 14 JAN 2008
- Published Print: 1 JAN 2006
Print ISBN: 9781405127066
Online ISBN: 9780470753231
- adjuvant therapy;
- colon cancer;
- patient population;
This chapter contains section titled:
How is 5-FU best administered in the adjuvant setting?
What survival outcome should be the primary endpoint for adjuvant colorectal trials?
What is the role of oxaliplatin in the adjuvant setting?
Should irinotecan be used in adjuvant treatment?
What is the role of capecitabine in stage III colon cancer adjuvant treatment?
Should stage II colon cancer patients receive treatment?
Does microsatellite instability predict which patients will benefit from adjuvant treatment?
Should the biologic agents cetuximab or bevacizumab be added to treatment regimens?